Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer

Abstract

Liquid biopsy, which generally refers to the analysis of biological components such as circulating nuclear acids and circulating tumor cells in body fluids, particularly in peripheral blood, has shown good capacity to overcome several limitations faced by conventional tissue biopsies. Emerging evidence in recent decades has confirmed the promising role of liquid biopsy in the clinical management of various cancers, including colorectal cancer, which is one of the most prevalent cancers and the second leading cause of cancer-related deaths worldwide. Despite the challenges and poor clinical outcomes, patients with metastatic colorectal cancer can expect potential clinical benefits with liquid biopsy. Therefore, in this review, we focus on the clinical prospects of liquid biopsy in metastatic colorectal cancer, specifically with regard to the recently discovered various biomarkers identified on liquid biopsy. These biomarkers have been shown to be potentially useful in multiple aspects of metastatic colorectal cancer, such as auxiliary diagnosis of metastasis, prognosis prediction, and monitoring of therapy response.

Potential Role of 8-Hydroxyguanosine and some Pro Inflammatory Cytokines as Biomarkers in Colorectal Cancer Iraqi Patients

“…Moreover, untimely identification of colon cancer patients at high level perilous of progression spread of tumor in colon cancer is critical for early interfering to ameliorate colon cancer consequence. Current therapy for colon cancer patients comprised, medicament, immunotherapy, goal remedy and surgical resection 3 . Elevated concentration of oxygen radicals has been identified in approximately all cancers, which attribute to their role as a best-identifiable constituent in malignancy.…”

A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study

“…With the use of liquid biopsy, the two heterogeneities can now be diagnosed, thus contributing to the more accurate prediction for molecular targeted therapy. Liquid biopsy includes ctDNA, circulating tumor cells, and circulating non-coding RNAs, with ctDNA being the most widely used because of its high sensitivity [5,17,18]. In this present study, we try to clarify the utility of liquid biopsy in predicting the efficacy of anti-EGFR therapy and mechanism of primary and secondary resistance in terms of spatial and temporal heterogeneity.…”

Intracellular and extracellular factors of colorectal cancer liver metastasis: a pivotal perplex to be fully elucidated

“…Some small-scale cohort studies have discovered that various types of circulating molecules can be used as potential biomarkers for prognostic prediction of CRLM. However, their actual clinical applications were still minimal [ 122 ]. There was evidence that apoptotic circulating tumor cell (CTC) was a possible prognostic marker for CRC metastasis to the liver or other metastases.…”

“…The central question is the mechanisms underlying the formation of metastatic clones, like whether metastatic capacity is an advantage that has been selected during tumor evolution in the primary tumor or just an unselected, incidental consequence of tumor progression [ 43 ]. Because only a few “fit” subclones among all clones can survive and give rise to metastasis in a distant organ, several cancer initiation evolution models have been proposed to explain metastatic progression, and the feasibility of these models in explaining the development of metastasis is still being explored [ 122 ]. Tumor initiation is thought to be driven by the sequential stepwise acquisition of genetic alternations involving driver gene mutations in the classical “linear progression model” (Note: this should be distinguished from the “linear progression model” in metastatic evolution).…”